SBIR/STTR Research Award
Efficacy and Safety of Fresh SVF For Combat Veterans with PTSD and Blast Trauma Exposure
Award amount
$750,000Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2022Award details
- Awarding agency
- Department of Defense
- Branch
- Air Force
- Recipient company
- Cell Surgical Network Corporation
- Proposal award date
- 2022-08-04
- Contract end date
- 2023-11-07
- UEI
- LQ77JMMJUMK5
- Solicitation number
- X21.1
- Topic code
- AF211-DCSO1
Research abstract
Objectives To evaluate the safety of autologous adipose-derived stromal vascular fraction (SVF) for the mitigation of symptoms of blast traumatic brain injury (bTBI) in affected combat veterans exhibiting symptoms of posttraumatic stress disorder (PTSD) that have had exposure to military grade blast explosions. Secondly, to evaluate the efficacy of SVF for bTBI against a control group.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- TACFI KestrelX
- Low-Cost Rapid-Cadence Hypersonic Launch
- Electrified Propulsion Aircraft Rapid Design Tools
- Low Probability of Intercept/Low Probability of Detection (LPI/LPD) Multi-band Mesh Networks
- Space Prognostic AI Custodian Ecosystem (SPAICE) - TACFI
Research funding history
2 SBIR/STTR records share this UEI (2019–2022). Reported award amounts total $800,000. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II
Agencies: Department of Defense